Rare diseases
Investigational molecules
Locations
Parc Del Tauli 1, 08208 Sabadell, Spain
Parc Tauli Hospital Universitari in Sabadell, Spain specialises in clinical trials of conditions such as Psoriatic arthropathy, Prostate cancer metastatic, Non-small cell lung cancer, Hormone-refractory prostate cancer, and other specialisations. This site conducts important research.
The medical center is at the forefront of research in psoriatic arthritis, focusing on innovative treatments that aim to improve patient outcomes. The center's research includes evaluating the efficacy and safety of novel therapeutic agents.
These studies contribute to a deeper understanding of treatment responses and long-term management strategies for psoriatic arthritis.
Research at the center is advancing the treatment of major depressive disorder (MDD), particularly in patients with moderate-to-severe anhedonia. The focus is on adjunctive therapies that enhance the efficacy of existing antidepressant treatments.
These efforts aim to address unmet needs in MDD treatment, offering hope for improved quality of life for patients.
The center is pioneering research in the treatment of advanced or metastatic solid tumors, exploring the safety and efficacy of novel oral agents and combination therapies.
This research is crucial for developing new therapeutic options for patients with resistant forms of cancer.
Innovative research at the center is focused on non-muscle invasive bladder cancer, evaluating combination therapies to improve response rates and patient outcomes.
These studies are essential for advancing treatment protocols and improving survival rates in bladder cancer patients.
The center is conducting cutting-edge research in metastatic colorectal cancer, focusing on rechallenge strategies and novel therapeutic combinations to enhance treatment efficacy.
This research is pivotal in developing personalized treatment plans for colorectal cancer patients.
Research at the center is advancing the understanding and treatment of systemic lupus erythematosus (SLE), focusing on novel agents that target disease activity and improve patient outcomes.
These studies are crucial for developing effective therapies that address the complex nature of SLE.
The center is leading research in primary biliary cholangitis (PBC), focusing on treatments that alleviate symptoms and improve quality of life for patients.
This research is vital for developing comprehensive care strategies for PBC patients.
Research at the center is focused on improving outcomes for patients with chronic liver disease, exploring the potential of zinc acexamate to enhance prognosis and reduce clinical events.
This research is essential for developing new therapeutic approaches to manage chronic liver conditions.
The center is at the forefront of research in cystic fibrosis, evaluating the long-term safety and efficacy of combination therapies to improve patient outcomes.
This research is crucial for advancing treatment options and enhancing the quality of life for cystic fibrosis patients.
Research at the center is focused on optimizing chemotherapy regimens for upper tract urothelial carcinoma, assessing the feasibility and efficacy of neo-adjuvant versus adjuvant approaches.
This research is vital for developing personalized treatment strategies for urothelial carcinoma patients.
The center is pioneering research in renal cell carcinoma, exploring combination therapies to improve progression-free survival and patient outcomes.
This research is essential for advancing treatment protocols and improving survival rates in renal cell carcinoma patients.
Research at the center is advancing the treatment of non-alcoholic steatohepatitis (NASH), focusing on novel agents that target fibrosis and improve liver health.
This research is crucial for developing effective therapies that address the complex nature of NASH.
The center is leading research in Angelman Syndrome, focusing on the safety and tolerability of novel therapeutic agents to improve patient outcomes.
This research is vital for developing comprehensive care strategies for Angelman Syndrome patients.
The center is conducting cutting-edge research in colorectal cancer, focusing on novel therapeutic combinations to enhance treatment efficacy and patient outcomes.
This research is pivotal in developing personalized treatment plans for colorectal cancer patients.
The center is at the forefront of research in pruritus associated with primary biliary cholangitis, evaluating the efficacy of novel agents to alleviate symptoms and improve quality of life.
This research is crucial for developing comprehensive care strategies for PBC patients.
Research at the center is focused on the long-term safety of novel therapies for fibroinflammatory liver diseases, aiming to improve patient outcomes and quality of life.
This research is essential for developing new therapeutic approaches to manage fibroinflammatory liver conditions.
The center is pioneering research in rheumatoid arthritis, focusing on the safety and efficacy of novel therapeutic agents to improve patient outcomes.
This research is crucial for advancing treatment options and enhancing the quality of life for rheumatoid arthritis patients.
Research at the center is focused on optimizing resuscitation strategies for acute pancreatitis, evaluating the efficacy and safety of different fluid therapies.
This research is vital for developing personalized treatment strategies for acute pancreatitis patients.
The center is at the forefront of research in HER2-positive early breast cancer, focusing on optimizing treatment regimens to improve patient outcomes and reduce treatment burden.
This research is crucial for advancing treatment protocols and improving survival rates in breast cancer patients.
Research at the center is advancing the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), focusing on novel agents that improve progression-free survival and patient outcomes.
This research is essential for developing effective therapies that address the complex nature of GEP-NETs.
The center is leading research in the prophylaxis of venous thromboembolic disease, focusing on optimizing treatment regimens to prevent VTE events in high-risk patients.
This research is vital for developing comprehensive care strategies for patients at risk of VTE.
Research at the center is focused on advancing the treatment of ulcerative colitis and Crohn's disease, evaluating the efficacy of novel agents in pediatric populations.
This research is crucial for developing effective therapies that address the complex nature of inflammatory bowel diseases.
The center is at the forefront of research in eosinophilic esophagitis, focusing on novel agents that reduce esophageal inflammation and improve patient outcomes.
This research is essential for developing comprehensive care strategies for eosinophilic esophagitis patients.
Research at the center is focused on optimizing treatment strategies for hepatotoxicity, evaluating the efficacy and safety of novel agents to improve liver health.
This research is vital for developing personalized treatment strategies for hepatotoxicity patients.
The center is pioneering research in non-small cell lung cancer (NSCLC), focusing on combination therapies to improve progression-free survival and patient outcomes.
This research is crucial for advancing treatment protocols and improving survival rates in NSCLC patients.
Research at the center is advancing the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), focusing on novel agents that improve patient outcomes and quality of life.
This research is essential for developing effective therapies that address the complex nature of CIDP.
The center is leading research in bladder cancer, focusing on combination therapies to improve treatment efficacy and patient outcomes.
This research is vital for developing comprehensive care strategies for bladder cancer patients.
Research at the center is focused on optimizing treatment strategies for castration resistant prostate cancer, evaluating the efficacy of novel therapeutic combinations.
This research is crucial for advancing treatment options and enhancing the quality of life for prostate cancer patients.
The center is at the forefront of research in Sjögren’s syndrome, focusing on novel agents that improve disease activity and patient outcomes.
This research is essential for developing comprehensive care strategies for Sjögren’s syndrome patients.
Research at the center is focused on optimizing treatment regimens for bacteremia, evaluating the efficacy and safety of different antibiotic durations.
This research is vital for developing personalized treatment strategies for bacteremia patients.
The center is pioneering research in squamous cell carcinoma of the anal canal, focusing on combination therapies to improve treatment efficacy and patient outcomes.
This research is crucial for advancing treatment protocols and improving survival rates in anal canal carcinoma patients.
Research at the center is advancing the treatment of Prader-Willi syndrome, focusing on novel agents that reduce hyperphagia and improve patient outcomes.
This research is essential for developing comprehensive care strategies for Prader-Willi syndrome patients.
Clinical trials currently enrolling participants at this site.
SpainSpainSpainSpainSpainSpainSpainSpainSpainSpainSpainSpainMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
